said on Tuesday its over-the-counter nasal spray as a treatment for suspected opioid overdose would be reviewed on a priority basis by the U.S. health regulator.
The agency will make its decision by March 29 and its priority review status puts Narcan on track to become the first naloxone-based drug to be sold over the counter, Benchmark analyst Robert Wasserman said. There are legal barriers limiting access to naloxone in some states, and even in others the drug is not always available to those most at risk of an overdose.
Government data estimates that there were more than 100,000 drug-related overdose deaths in the country during 2021, a near 15% increase from the year earlier.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: